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We recently reported that glycated albumin (GA) is increased in subjects with longer duration of diabetes and with decreased
insulin secretory function. Based on this, we investigated whether GA increases with time relative to glycated hemoglobin (HbA
1c)
and the association between GA and beta-cell function. We analyzed 340 type 2 diabetes patients whose serum GA and HbA1c
levels had been repeatedly measured over 4 years. We assessed the pattern of changes with time in glycemic indices (GA, HbA
1c,
and GA/HbA
1c ratio) and their relationship with beta-cell function. In all patients, glycemic indices decreased and maintained low
levels around 15 and 27 months. However, from 39 months to 51 months, GA significantly increased but HbA
1c tended to increase
without statistical significance. We defined ΔGA/HbA
1c as the difference between the nadir point (at 15 to 27 months) and the end
point (at 39 to 51 months) and found that ΔGA/HbA
1c was positively correlated with diabetes duration and negatively related to
beta-cell function. In multivariable linear regression analyses, ΔGA/HbA
1c was independently associated with diabetes duration.
In conclusion, this study demonstrated that serum GA levels increase relative to HbA
1c levels with time.
1. Introduction
Glucose monitoring is essential for the appropriate care and
treatment of patients with diabetes in order to avoid diabetic
complications and hypoglycemia. An accurate measure of
glucose level allows physicians and patients to make optimal
decisions about food, physical activity, and medications [1].
Of the glycemic indices, the American Diabetes Association
recommends glycated hemoglobin (HbA
1c) testing in all
diabetic patients as an initial assessment and then as a part
of continuing care [2]. This recommendation is derived from
clinical data that shows that HbA
1c reflects average glycemic
status over 2-3 months and predicts diabetic complications
[3, 4]. Although HbA
1c provides useful information, it might
be inadequate in clinical situations such as anemia, renal
insufficiency, and gestational diabetes. Glycated albumin
(GA) has been gaining popularity as an indicator in several
physiologic and pathologic conditions [5] because it provides
more information than the gold standard HbA
1c. In line with
this trend, we have demonstrated the clinical relevance of
GA in type 2 diabetes mellitus (T2D) with insulin secretory
dysfunction rather than insulin resistance [6], fluctuating or
poorly controlled glycemic excursions [7], and progressing
atherosclerosis [8].
In the natural course of T2D, however, beta-cell function
decreases as duration of diabetes increases [9]. Moreover,
glycemic excursions worsen due to decreased beta-cell func-
tion [10]. In a recent cross-sectional study, we reported that
the levels of GA/HbA
1c were significantly elevated in subjects
with long diabetic duration, largely attributed to the inverse
relationships between GA and pancreatic beta-cell secretory
indices [11], and suggested that clinicians should be careful
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in interpreting GA as only an indicator of glycemic control
in T2D cases of longer duration. However, no longitudinal
studies investigating the change in GA and HbA
1c over time
in patients with T2D have been published.
In this longitudinal observational study, we investigated
the changing pattern of glycemic indices such as GA, HbA
1c,
and GA/HbA
1c over 4 years in order to determine whether
GA increases more with time relative to HbA
1c in subjects
with T2D. We also investigated which clinical and biochemi-
cal parameters are associated with changes in the GA/HbA
1c
ratio.
2. Research Design and Methods
2.1. Subjects and Data Collection. In this longitudinal obser-
vational study, we recruited patients with T2D who had
enrolled in previous studies [6, 7] betweenMay 2009 and June
2011 and who were followed up in June 2014. Using electronic
medical records, we reviewed and rechecked demographic
and clinical data for age, gender, metabolic parameters, and
duration of diabetes. The diabetic duration was defined from
the date the patients were first diagnosed with diabetes by
blood tests or by patient recall from interviews.
To investigate the changes in glycemic indices with time,
we tried to include patients whose duration of diabetes was
less than 5 years. Patients were included if they were (1) aged
≥20 years, (2) had repeated laboratory data for both HbA
1c
and GA up to the final follow-up point, and (3) had under-
gone a baseline standardized liquid meal test (Ensure, Meiji
Dairies Corporation, Tokyo, Japan; 500 kcal, 17.5 g fat (31.5%),
68.5 g carbohydrate (54.5%), and 17.5 g protein (14.0%)) after
an overnight fast. Patients were excluded if they had any
medical conditions that could alter HbA
1c or GA levels
such as liver cirrhosis or chronic kidney diseases (estimated
glomerular filtration rate (GFR) by chronic kidney disease
epidemiology collaboration formula <60mL/min/1.73m2),
pregnancy, or hematologic disorders or if they were being
treated with steroids.
The protocol of this study was approved by the Insti-
tutional Review Board at Severance Hospital (IRB num-
bers 4-2009-0656, 4-2012-0398, and 4-2014-0507). Written
informed consent for this study was not required by the
Institutional Review Board because researchers only accessed
the database for analysis purposes, and personal information
was not used.
2.2. LaboratoryMeasurements. Thebaseline glycemic indices
(GA, HbA
1c, and GA/HbA1c) were defined as the values
measured at enrollment. Subsequently, serumGA andHbA
1c
were measured every 3 or 6 months. The end point glycemic
indices of each subject were measured between 39 and 51
months. For glucose and C-peptide analyses, blood samples
were collected at 0 and 90min (basal and stimulated values)
as part of the standardized liquid meal test. Pancreatic beta-
cell functions in the context of ambient insulin secretory
function were assessed using the following indices: (1)
PCGR (stimulated C-peptide level/stimulated glucose level ×
100), (2) C-peptide increment (ΔC-peptide = stimulated C-
peptide − basal C-peptide), and (3) C-peptide-genic index
[CGI = (stimulatedC-peptide− basal C-peptide)/(stimulated
glucose − basal glucose)]. Measurement techniques included
the hexokinase method for glucose and high-performance
liquid chromatography using Variant II Turbo (Bio-Rad
Laboratories, Hercules, CA) for HbA
1c. Serum GA was
analyzed by an enzymatic method using an albumin-specific
proteinase, ketoamine oxidase, an albumin assay reagent
(LUCICAGA-L; Asahi Kasei Pharma Co., Tokyo, Japan), and
a Hitachi 7699 P module autoanalyzer (Hitachi Instruments
Service, Tokyo, Japan). GA values were calculated from the
ratio of GA to total serum albumin and expressed as a
percentage. Serum C-peptide levels were measured in dupli-
cate using an immunoradiometric assay method (Beckman
Coulter, Fullerton, CA).
2.3. Statistical Analysis. All continuous variables were pre-
sented as mean ± standard deviation (SD) or median
(quartiles) or as mean ± standard error (SE) for variables
on the graphs. Categorical variables were described as N
(%). Differences were analyzed using Student’s t-test for the
continuous variables and the chi-square test for categorical
variables.
Repeated measured analysis of variance (ANOVA) with
Bonferroni correction and paired t-test were used to deter-
mine the significance of differences in glycemic indices
according to duration of diabetes. We compared GA, HbA
1c,
and GA/HbA
1c levels at baseline and 3, 15, 27, and 39 to 51
months after enrollment in all patients who had glycemic
values available at that time point. Because all glycemic
indices reached their lowest level between 15 and 27 months
(arbitrarily defined nadir point), we defined ΔGA/HbA
1c as
the difference in GA/HbA
1c between the end point (39 to
51 months) and nadir point (15 to 27 months). One-way
ANOVA with Tukey correction was used to compare the
differences of duration of diabetes and PCGR according to
the tertiles of ΔGA/HbA
1c ratio. Multivariable linear regres-
sion analysis was performed to determine the independent
relationship of the studied variables including duration of
diabetes associated with ΔGA/HbA
1c increase. Statistical
analyses were performed using PASW Statistics version 18.0
for Windows (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Study Population Characteristics. A total of 340 subjects
(71% men, mean age 61.3 ± 11.6 years) were enrolled in this
study. The patient characteristics of the cohort are shown
in Table 1. The mean body mass index (BMI) was 25.4 ±
3.6 kg/m2 and the prevalence of hypertension was 57% (𝑛 =
195). Median duration of diabetes and levels of mean HbA
1c
were 1 (range: 0–5.0) year and 7.0% + 0.9%, respectively. We
also measured baseline insulin secretory beta-cell function
indices such as PCGR (3.24 ± 2.1), ΔC-peptide level (4.13 ±
2.6), and CGI (0.08±0.4). All glycemic indices, GA (19.3±6.6
versus 16.5 ± 4.9), HbA
1c (7.7 ± 1.6 versus 7.0 ± 1.2), and
GA/HbA
1c (2.47 ± 0.5 versus 2.33 ± 0.4), were decreased at
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Table 1: Baseline characteristics of the study population.
Variables All (𝑁 = 340)
Demographics
Age (years) 61.3 ± 11.6
Male,𝑁 (%) 204 (71)
BMI (kg/m2) 25.4 ± 3.6
Waist circumference (cm) 88.1 ± 9.0
Hypertension,𝑁 (%) 195 (57)
Duration of diabetes (years) 1.0 (0–5.0)
Biochemistry profiles
Creatinine (mg/dL) 0.93 ± 0.2
Estimated GFR (mL/min/1.73m2) 81.5 ± 17.7
Albumin (g/dL) 4.6 ± 0.4
Total cholesterol (mg/dL) 177.2 ± 48.5
Triglyceride (mg/dL) 152.5 ± 110.7
HDL-cholesterol (mg/dL) 47.7 ± 14.3
LDL-cholesterol (mg/dL) 99.7 ± 38.7
Beta-cell function indices at baseline
Basal glucose (mg/dL) 138.0 ± 50.9
Stimulated glucose (mg/dL) 231.8 ± 87.3
Basal C-peptide (ng/mL) 2.35 ± 1.2
Stimulated C-peptide (ng/mL) 6.50 ± 3.3
ΔC-peptide (ng/ml) 4.13 ± 2.6
PCGR 3.24 ± 2.1
CGI 0.08 ± 0.4
Glycemic indices
GA at baseline (%) 19.3 ± 6.6
HbA1c at baseline (%) 7.7 ± 1.6
HbA1c at baseline (mmol/mol) 60.8 ± 16.9
GA/HbA1c ratio at baseline 2.47 ± 0.5
GA at end point (%) 16.5 ± 4.9
HbA1c at end point (%) 7.0 ± 1.2
HbA1c at end point (mmol/mol) 53.2 ± 13.1
GA/HbA1c ratio at end point 2.33 ± 0.4
Mean GA (%) 16.5 ± 4.0
Mean HbA1c (%) 7.0 ± 0.9
Medications at baseline
Insulin,𝑁 (%) 63 (19)
Metformin,𝑁 (%) 221 (65)
DPP-IV inhibitor,𝑁 (%) 59 (17)
Thiazolidinediones,𝑁 (%) 40 (12)
Sulfonylurea,𝑁 (%) 88 (26)
Medications at 27 months
Insulin,𝑁 (%) 52 (15)
Metformin,𝑁 (%) 254 (75)
DPP-IV inhibitor,𝑁 (%) 98 (29)
Thiazolidinediones,𝑁 (%) 65 (19)
Sulfonylurea,𝑁 (%) 99 (29)
Continuous variables were described as mean ± SD or median (quartiles),𝑁
(%) for categorical variables.
BMI, body mass index; GFR, glomerular filtration rate; GA, glycated
albumin; CGI, C-peptide-genic index; PCGR, postprandial C-peptide to
glucose ratio.
final follow-up compared to those at baseline. At the time of
enrollment, the patients were being treated with metformin
(221 patients; 65% of the study population), sulfonylurea (88;
26%), DPP-IV inhibitors (59; 17%), or insulin (63; 19%).
Table 2: Univariate linear regression analysis to determine the
variables associated with ΔGA/HbA1c.
Variables STD 𝛽 𝑝
Age (year) 0.063 0.246
BMI (kg/m2) −0.063 0.251
Waist circumference (cm) 0.004 0.940
Estimated GFR (mL/min/1.73m2) −0.032 0.552
Albumin (g/dL) 0.008 0.886
Total cholesterol (mg/dL) −0.029 0.599
Triglyceride (mg/dL) −0.080 0.141
HDL-cholesterol (mg/dL) 0.023 0.674
LDL-cholesterol (mg/dL) −0.007 0.903
GA at baseline (%) 0.166 0.002
HbA1c at baseline (%) 0.017 0.753
Mean GA (%) 0.345 <0.001
Mean HbA1c (%) 0.128 0.018
Duration of diabetes (year) 0.187 0.001
ΔC-peptide (ng/mL) −0.139 0.011
PCGR −0.145 0.007
CGI −0.059 0.284
BMI, body mass index; GFR, glomerular filtration rate; GA, glycated
albumin; PCGR, postprandial C-peptide to glucose ratio; CGI, C-peptide-
genic index. Values with statistical significance are printed in bold.
3.2. Glycated Albumin and GA/HbA1c Ratio Levels Increased
Relative to HbA1c Levels over Time. In all patients, both levels
of GA (16.1% ± 4.0%) and GA/HbA
1c ratio (2.30 ± 0.4)
improved and reached the nadir points on glucose control at
15months (Figure 1). From 15months to 39months, the nadir
glycemic indices were stably maintained. From 39 months
to 51 months, GA significantly increased (16.1% ± 4.8% to
17.5% ± 4.9%, 𝑝 = 0.028), but HbA
1c tended to increase
without statistical significance (6.9% ± 1.0% to 7.1% ± 1.2%,
𝑝 = 0.389). The levels of GA at 27 and 39 months (𝑝 = 0.029
and 0.028, resp.) as well as GA/HbA
1c ratio at 15 and 27
months (𝑝 = 0.038, 𝑝 = 0.039) were significantly lower
than at 51 months (Figures 1(a) and 1(b)). However, statistical
differences in HbA
1c between each time point (3, 15, 27,
and 39 months) and the last time point (51 months) were
not significant except for baseline (Figure 1(c)). In sum, GA
levels and the GA/HbA
1c ratio, but not HbA1c levels, were
significantly increased at the final follow-up compared with
those at the nadir time point (Figure 1(d)).
3.3. Associations between ΔGA/HbA1c and Clinical and Bio-
chemical Parameters. Since the GA/HbA
1c ratio significantly
increased from the nadir point to the final follow-up point,
which was designated as ΔGA/HbA
1c (Figure 1(e)), we tried
to determine the clinical and biochemical parameters that
are associated with ΔGA/HbA
1c (Table 2). In the univariate
linear regression analysis, duration of diabetes (standardized
𝛽 coefficient (STD 𝛽) = 0.187, 𝑝 = 0.001), mean GA (STD
𝛽 = 0.345, 𝑝 < 0.001), and mean HbA
1c (STD 𝛽 = 0.128,
𝑝 = 0.018) were positively associated with ΔGA/HbA
1c. On
the other hand, beta-cell function indices were negatively
related toΔGA/HbA
1c. In particular, PCGR (STD 𝛽 = −0.145,
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Figure 1: Changing patterns of glycemic indices over 4 years. (a) GA, (b) GA/HbA
1c ratio, (c) HbA1c, (d) changing patterns of glycemic
indices, (e) ΔGA/HbA
1c, calculated by end point GA/HbA1c – nadir point GA/HbA1c. Data are presented as mean with SE.
∗𝑝 < 0.001,
†𝑝 < 0.05 for the comparison with 51 months.
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Figure 2: Correlations between ΔGA/HbA
1c and duration of diabetes, beta-cell function. (a, b) Differences of duration of diabetes (a) and
PCGR (b) in subjects according to the tertiles of ΔGA/HbA
1c. (c, d) Differences of ΔGA/HbA1c (c) and PCGR (d) in subjects according to
duration of diabetes. †𝑝 < 0.05, ‡𝑝 < 0.01, ∗𝑝 < 0.001; ΔGA/HbA
1c (%) = ΔGA/HbA1c/nadir point GA/HbA1c ∗ 100.
𝑝 = 0.007) was more strongly associated with ΔGA/HbA
1c
than ΔC-peptide (STD 𝛽 = −0.139, 𝑝 = 0.011).
We classified study subjects according to tertiles of
ΔGA/HbA
1c. Individuals in higher tertiles for ΔGA/HbA1c
had longer duration of diabetes (2.4 versus 3.7 versus 4.7
years; tertile 1 versus tertile 3, 𝑝 = 0.013) and lower levels of
PCGR (3.5 versus 3.5 versus 2.7; tertile 1 versus tertile 3, 𝑝 =
0.011; tertile 2 versus tertile 3, 𝑝 = 0.021) (Figures 2(a) and
2(b)). Moreover, study subjects were categorized into three
groups based on duration of diabetes (Group A: ≤6 months,
𝑛 = 153; Group B: >6 months and ≤5 years, 𝑛 = 111; Group
C: >5 years, 𝑛 = 76) to investigate the impact of diabetes
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Table 3: Multivariable linear regression analyses to determine the variables associated with ΔGA/HbA1c.
Models Model 1 Model 2 Model 3 Model 4 Model 5
Variables Conventional confounders
Model 1
+ PCGR
Model 2
+ duration of diabetes
Model 3
+ mean GA
Model 3
+ mean HbA1c
STD 𝛽 𝑝 STD 𝛽 𝑝 STD 𝛽 𝑝 STD 𝛽 𝑝 STD 𝛽 𝑝
DPP-IV
inhibitor use −0.111 0.049 −0.109 0.053 −0.089 0.111 −0.084 0.133 −0.088 0.116
PCGR — — −0.161 0.009 −0.111 0.080 −0.059 0.396 −0.106 0.113
Duration of
diabetes — — 0.172 0.005 0.166 0.007 0.170 0.007
Conventional confounders: age (years), sex (0 = female, 1 = male), body mass index (kg/m2), waist circumference (cm), and estimated glomerular filtration
rate (mL/min/1.73m2).
PCGR, postprandial C-peptide to glucose ratio; STD 𝛽, standardized 𝛽 coefficient. Values with statistical significance are printed in bold.
duration on ΔGA/HbA
1c ratio and PCGR. The ΔGA/HbA1c
ratios (expressed as percentages) were significantly elevated
in patients with diabetes of duration >5 years compared to
other groups (Figure 2(c)), whereas PCGR was decreased in
patients with longer duration of diabetes (Figure 2(d)).
3.4. ΔGA/HbA1c Was Independently Associated with Duration
of Diabetes. Multivariable linear regression models were
applied to determine the clinical and laboratory variables
associated withΔGA/HbA
1c (Table 3).We focused on certain
parameters that can directly or indirectly reflect the insulin
secretory function, such as PCGR, duration of diabetes, and
medication history of DPP-IV inhibitor which can effectively
reduce postprandial glucose. After adjustment for clinically
important variables such as age, sex, BMI, waist circum-
ference, and estimated GFR in model 1, history of DPP-
IV inhibitor use was negatively associated with ΔGA/HbA
1c
(STD 𝛽 = −0.111, 𝑝 = 0.049). After additional inclusion of
PCGR inmodel 2, PCGR showed significant correlation with
ΔGA/HbA
1c (STD𝛽=−0.161,𝑝 = 0.009), but history ofDPP-
IV inhibitor use lost its significance. In model 3, duration of
diabetes was further adjusted and the significant correlation
of PCGRwith ΔGA/HbA
1c disappeared (STD 𝛽 = −0.111, 𝑝 =
0.080). However, duration of diabetes was still independently
associated with ΔGA/HbA
1c (STD 𝛽 = 0.172, 𝑝 = 0.005).
Moreover, this association remained significant even after
adjustment for glycemic status of subjects (inclusion of mean
GA in model 4 and mean HbA
1c in model 5, resp.).
Additionally, we conducted multiple linear regression
analyses to determine variables associated with PCGR at
baseline (Supplementary Table 1 in Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2015/576306).
PCGR showed the strongest relationshipwithmeanGA (STD
𝛽=−0.336,𝑝 < 0.001). It also had significant correlationwith
duration of diabetes (STD 𝛽 = −0.133, 𝑝 = 0.010) and insulin
use (STD 𝛽 = −0.119, 𝑝 = 0.029) (model 1). To evaluate the
association between PCGR and ΔGA/HbA
1c, model 2 was
developed, which showed a significant negative relationship
(STD 𝛽 = −0.107, 𝑝 = 0.032).
4. Discussion
Evidence has accumulated on the clinical relevance of GA
as a glycemic index. However, the optimal use of GA as
a glucose monitoring tool has not been fully investigated.
Based on a previous cross-sectional study that showed that
GA values are significantly influenced by the duration of
T2D in cases where beta-cell function gradually decreases
with time, we hypothesized that the ratio of GA to HbA
1c
might not be constant over time. In this study of more than
4 years, we assessed glycemic excursion by measuring HbA
1c
and GA and investigated discrepancy between two glycemic
indices according to multiple time points. This study has
three main findings: first, we found an initial sharp decrease
in these glycemic indices, followed by maintenance at a low
level, and then a gradual increase. Unlike for GA, the HbA
1c
increase was statistically insignificant. Second, the change
in GA/HbA
1c ratios, defined as the difference between the
nadir point and the end point, was independently associated
with baseline duration of diabetes. Third, impaired beta-
cell function accounted for the association between longer
duration of diabetes and increase in GA relative to HbA
1c,
as well as the increase in the GA/HbA
1c ratio.
Because HbA
1c is formed via a nonenzymatic glyca-
tion process of hemoglobin in erythrocytes [12], medical
conditions such as pregnancy, hemolytic anemia, chronic
kidney disease, or end stage renal disease with dialysis
could alter HbA
1c levels. In those cases, GA may be a
more reliable marker than HbA
1c [5]. In contrast to HbA1c
formation, which requires intracellular glucose and protein
metabolism, GA is formed directly via an extracellular
nonenzymatic glycation process in plasma.However, medical
conditions associated with albumin metabolism such as
obesity, hyperthyroidism, and nephrotic syndrome, as well
as glucocorticoid treatment [5], are known to affect GA
levels. To avoid complications, we did not include patients
with liver cirrhosis, chronic kidney diseases, pregnancy, and
hematologic disorders or those who were being treated with
steroid therapy.
With respect to the clinical relevance of the GA/HbA
1c
ratio, it is known that the ratio is significantly correlated
with insulin secretory beta-cell function but not with insulin
resistance [6]. Recent study also showed that lower insulin
secretory capacity predicted increased levels of GA/HbA
1c
ratio in subjects with T2D [13]. Moreover, the GA/HbA
1c
ratio in patients with T1D and T2Dmore accurately reflected
glucose excursion [7, 14–16] and diabetic vasculopathy [8, 17]
than HbA
1c alone. The GA/HbA1c ratio was significantly
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higher in T2D patients treated with insulin than in those
treated with either diet or oral hypoglycemic agents [7, 18].
This observation might explain why history of insulin use is
associated with either significant hyperglycemia or decreased
beta-cell function. Our study also showed that ΔGA/HbA
1c
between end point and nadir point is significantly associated
with decreased insulin secretory function-related clinical and
laboratory variables such as baseline and mean GA, mean
HbA
1c PCGR, ΔC-peptide, and diabetic duration (Table 2).
Of the assessed glycemic indices, baseline HbA
1c did not
predict the changes in the GA/HbA
1c ratio. With respect
to the effect of insulin secretory factors on GA values, a
recent cross-sectional study reported that GA levels sig-
nificantly increased more in patients with longer duration
of T2D and impaired beta-cell function measured by ΔC-
peptide regardless of HbA
1c levels [11]. Consistent with this
finding, our longitudinal study also showed that patients
with higher levels of ΔGA/HbA
1c had longer duration of
diabetes and lower levels of PCGR (Figure 2). Furthermore,
PCGR representing beta-cell function was associated with
diabetic duration and insulin use at baseline and mean GA
but not with mean HbA
1c. Based on these findings, we could
infer that patients with T2D of longer duration and with
higher GA/HbA
1c are more likely to have impaired beta-cell
function and need insulin.
Our study had several strengths. First, this study is a
longitudinal study with a long follow-up period of more
than 4 years, which allowed us to investigate the changes
in GA and HbA
1c levels over time. Second, about 80% of
participants had a relatively short duration of diabetes (≤5
years) at enrollment. Lastly, we conductedmixedmeal tests to
obtain basal and stimulatedC-peptide levels, whichwere then
used to calculate PCGR as a measure of beta-cell function.
That allowed for standardization of the stimulation calories
and glucose content. Because it can be easily calculated and
is a reliable indicator of beta-cell function, the PCGR is being
used more frequently to help determine the optimal antidia-
betic drug treatment [19, 20]. In our study, PCGR levels were
strongly associated with ΔC-peptide (𝑟 = 0.808, 𝑝 < 0.001)
which strongly predicted beta-cell function (Supplementary
Figure 1). In multivariable linear regression analyses, PCGR
was also associated with ΔGA/HbA
1c. However, because
the duration of diabetes strongly affects ΔGA/HbA
1c, after
adjusting for duration of diabetes, the association between
ΔGA/HbA
1c and PCGR disappeared (Table 3).
This study has the following limitations. First, we did not
measure beta-cell function or glucose levels during follow-
up period or at the end point. Thus, we did not prove that
the difference between GA and HbA
1c is caused by a decline
in beta-cell function during the follow-up period. Second,
since this is a retrospective study, the follow-up period varied
among the participants. Third, because we did not assess
changes in medication, we could not adjust for its effects.
5. Conclusions
Weconclude that both impaired beta-cell function and longer
duration of diabetes are associated with an increase in GA
relative to HbA
1c and an increase in the GA/HbA1c ratio.
The GA/HbA
1c ratio was significantly correlated with insulin
secretory beta-cell function and increased as duration of
diabetes increased. In this regard, clinicians should be extra
careful when interpreting GA and GA/HbA
1c ratio values
in subjects with longer duration of diabetes. Further well-
designed prospective studies enrolling larger populations are
warranted.
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